These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 30736358)

  • 1. Treatment and Prevention of Recurrent Clostridium difficile Infection with Functionalized Bovine Antibody-Enriched Whey in a Hamster Primary Infection Model.
    Heidebrecht HJ; Weiss WJ; Pulse M; Lange A; Gisch K; Kliem H; Mann S; Pfaffl MW; Kulozik U; von Eichel-Streiber C
    Toxins (Basel); 2019 Feb; 11(2):. PubMed ID: 30736358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters.
    Anosova NG; Brown AM; Li L; Liu N; Cole LE; Zhang J; Mehta H; Kleanthous H
    J Med Microbiol; 2013 Sep; 62(Pt 9):1394-1404. PubMed ID: 23518659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral Immunization with Nontoxigenic Clostridium difficile Strains Expressing Chimeric Fragments of TcdA and TcdB Elicits Protective Immunity against C. difficile Infection in Both Mice and Hamsters.
    Wang Y; Wang S; Bouillaut L; Li C; Duan Z; Zhang K; Ju X; Tzipori S; Sonenshein AL; Sun X
    Infect Immun; 2018 Nov; 86(11):. PubMed ID: 30150259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The protective effect of recombinant Lactococcus lactis oral vaccine on a Clostridium difficile-infected animal model.
    Yang XQ; Zhao YG; Chen XQ; Jiang B; Sun DY
    BMC Gastroenterol; 2013 Jul; 13():117. PubMed ID: 23865596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.
    Karczewski J; Zorman J; Wang S; Miezeiewski M; Xie J; Soring K; Petrescu I; Rogers I; Thiriot DS; Cook JC; Chamberlin M; Xoconostle RF; Nahas DD; Joyce JG; Bodmer JL; Heinrichs JH; Secore S
    Vaccine; 2014 May; 32(24):2812-8. PubMed ID: 24662701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety of whey protein concentrate derived from the milk of cows immunized against Clostridium difficile.
    Young KW; Munro IC; Taylor SL; Veldkamp P; van Dissel JT
    Regul Toxicol Pharmacol; 2007 Apr; 47(3):317-26. PubMed ID: 17293018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model.
    Qiu H; Cassan R; Johnstone D; Han X; Joyee AG; McQuoid M; Masi A; Merluza J; Hrehorak B; Reid R; Kennedy K; Tighe B; Rak C; Leonhardt M; Dupas B; Saward L; Berry JD; Nykiforuk CL
    PLoS One; 2016; 11(6):e0157970. PubMed ID: 27336843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models.
    Tian JH; Glenn G; Flyer D; Zhou B; Liu Y; Sullivan E; Wu H; Cummings JF; Elllingsworth L; Smith G
    Vaccine; 2017 Jul; 35(33):4079-4087. PubMed ID: 28669616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The recombinant Lactococcus lactis oral vaccine induces protection against C. difficile spore challenge in a mouse model.
    Guo S; Yan W; McDonough SP; Lin N; Wu KJ; He H; Xiang H; Yang M; Moreira MA; Chang YF
    Vaccine; 2015 Mar; 33(13):1586-95. PubMed ID: 25698490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deciphering the domain specificity of C. difficile toxin neutralizing antibodies.
    Cole LE; Li L; Jetley U; Zhang J; Pacheco K; Ma F; Zhang J; Mundle S; Yan Y; Barone L; Rogers C; Beltraminelli N; Quemeneur L; Kleanthous H; Anderson SF; Anosova NG
    Vaccine; 2019 Jun; 37(29):3892-3901. PubMed ID: 31122858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin.
    Warn P; Thommes P; Sattar A; Corbett D; Flattery A; Zhang Z; Black T; Hernandez LD; Therien AG
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6471-6482. PubMed ID: 27527088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clostridium difficile Toxoid Vaccine Candidate Confers Broad Protection against a Range of Prevalent Circulating Strains in a Nonclinical Setting.
    Quemeneur L; Petiot N; Arnaud-Barbe N; Hessler C; Pietrobon PJ; Londoño-Hayes P
    Infect Immun; 2018 Jun; 86(6):. PubMed ID: 29632249
    [No Abstract]   [Full Text] [Related]  

  • 13. A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model.
    Davies NL; Compson JE; Mackenzie B; O'Dowd VL; Oxbrow AK; Heads JT; Turner A; Sarkar K; Dugdale SL; Jairaj M; Christodoulou L; Knight DE; Cross AS; Hervé KJ; Tyson KL; Hailu H; Doyle CB; Ellis M; Kriek M; Cox M; Page MJ; Moore AR; Lightwood DJ; Humphreys DP
    Clin Vaccine Immunol; 2013 Mar; 20(3):377-90. PubMed ID: 23324518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toll-like receptor 5-dependent immunogenicity and protective efficacy of a recombinant fusion protein vaccine containing the nontoxic domains of Clostridium difficile toxins A and B and Salmonella enterica serovar typhimurium flagellin in a mouse model of Clostridium difficile disease.
    Ghose C; Verhagen JM; Chen X; Yu J; Huang Y; Chenesseau O; Kelly CP; Ho DD
    Infect Immun; 2013 Jun; 81(6):2190-6. PubMed ID: 23545305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mouse relapse model of Clostridium difficile infection.
    Sun X; Wang H; Zhang Y; Chen K; Davis B; Feng H
    Infect Immun; 2011 Jul; 79(7):2856-64. PubMed ID: 21576341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of two recombinant vaccines against Clostridioides difficile infection and immunogenicity in pregnant sows and neonatal piglets.
    Ramos CP; Siqueira WF; Viana LA; Cunha JLR; Fujiwara RT; Amarante VS; Souza TGV; Silva ROS
    Anaerobe; 2024 Oct; 89():102896. PubMed ID: 39127403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A chimeric protein comprising the glucosyltransferase and cysteine proteinase domains of toxin B and the receptor binding domain of toxin A induces protective immunity against Clostridium difficile infection in mice and hamsters.
    Wang YK; Yan YX; Kim HB; Ju X; Zhao S; Zhang K; Tzipori S; Sun X
    Hum Vaccin Immunother; 2015; 11(9):2215-22. PubMed ID: 26036797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease.
    Steele J; Mukherjee J; Parry N; Tzipori S
    J Infect Dis; 2013 Jan; 207(2):323-30. PubMed ID: 23125448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a new serological assay for the diagnosis of Clostridium difficile infections with prognostic value.
    von Bechtolsheim F; Varga A; Szereday L; Polgar B; Balassa T; Kocsis B; Peterfi Z; Miko E
    J Microbiol Methods; 2019 Dec; 167():105777. PubMed ID: 31733265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection.
    Wang H; Sun X; Zhang Y; Li S; Chen K; Shi L; Nie W; Kumar R; Tzipori S; Wang J; Savidge T; Feng H
    Infect Immun; 2012 Aug; 80(8):2678-88. PubMed ID: 22615245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.